Aortic Stenosis News and Research

RSS

Scottsdale Healthcare is first in Arizona to perform TAVR procedure

Scottsdale Healthcare Osborn Medical Center is the first hospital in Arizona to perform a new nonsurgical heart valve replacement procedure, the Transcatheter Aortic Valve Replacement (TAVR). TAVR valves are inserted via a catheter through the femoral artery, without requiring open heart surgery.

6 Jan 2012

UofL surgeons perform first transcatheter aortic-valve replacement at Jewish Hospital

Some individuals with severe aortic stenosis - also known as narrowing of the aortic valve in the heart - who are not well enough to undergo open heart surgery have a new treatment option thanks to a new procedure now available in Kentucky from University of Louisville physicians at Jewish Hospital.

4 Jan 2012

PET scans can provide insight into process that causes aortic stenosis

Patients with life-threatening heart valve disease could be helped with alternative scanning techniques that provide greater insight into the condition.

13 Dec 2011

Heart patients may experience fewer traumas with new invention

Heart patients may experience "a lot less" trauma with a new invention to mend leaky valves with minimum cutting, says inventor James Gammie, MD, an associate professor at the University of Maryland (UM) School of Medicine.

8 Dec 2011

Study examines potential cost effectiveness of TAVR versus SAVR

The cost effectiveness of transcatheter aortic valve implantation (TAVR) compared to surgical aortic valve replacement (SAVR) depends on whether TAVR is performed via the femoral artery or transapically, through a small incision in the chest, according to a new study.

11 Nov 2011

Positive results from InSeal's intravascular large bore puncture closure device trial

InSeal Medical Ltd., developer of percutaneous vascular closure devices for large bore punctures, today announced the successful treatment of three patients with its investigational intravascular large bore puncture closure device.

10 Nov 2011

Medtronic CoreValve System for direct aortic and subclavian implantation receives CE Mark

Medtronic, Inc. today announced it has received CE Mark for the Medtronic CoreValve System to be delivered using direct aortic access.

From Medtronic 7 Nov 2011

Medtronic highlights scientific sessions of interest on program for TCT 2011

Offering the broadest range of medical technology for the interventional and surgical treatment of cardiovascular disease, Medtronic, Inc. today highlighted scientific sessions of interest on the program for TCT 2011, which takes place Nov. 7-11 in San Francisco.

From Medtronic 5 Nov 2011

First U.S. transcatheter aortic heart valve implant performed at NewYork-Presbyterian/Columbia

NewYork-Presbyterian Hospital/Columbia University Medical Center today became the first in the United States to implant the SAPIEN transcatheter aortic heart valve as an FDA-approved standard of care.

5 Nov 2011

Edwards Life Sciences heart valve approved in the US

The U.S. Food and Drug Administration (FDA) this Wednesday approved the sale of Edwards Life Sciences Corp's Sapien heart valve for patients deemed too sick to have open-heart surgery.

3 Nov 2011

Medtronic initiates CoreValve System trial to treat severe aortic stenosis in Japan

Medtronic, Inc. today announced the first implant in a clinical trial in Japan that will evaluate the safety and effectiveness of the Medtronic CoreValve System.

From Medtronic 3 Nov 2011

Edwards Lifescience receives FDA approval for Sapien Transcatheter Heart Valve

The U.S. Food and Drug Administration today approved the first artificial heart valve that can replace an aortic heart valve damaged by senile aortic valve stenosis without open-heart surgery.

3 Nov 2011

CoreValve prosthesis shows promise against severe aortic stenosis

Among individuals 65 years and older, as many as 30 percent have aortic valve sclerosis or stenosis and as a result of their deteriorating health, cannot enjoy a normal lifestyle. "The aortic valve is a gatekeeper," says Marco Costa, MD, of University Hospitals (UH) Case Medical in Cleveland.

From Medtronic 1 Oct 2011

Engager Transcatheter Aortic Valve Implantation System pivotal trial to be conducted at 11 European centers

Medtronic, Inc. today announced the start of the Engager European Pivotal Trial to pursue CE Mark for the Engager Transcatheter Aortic Valve Implantation System in patients suffering from severe aortic stenosis.

From Medtronic 28 Sep 2011

TCT to showcase major scientific research breakthroughs in cardiovascular medicine

The Cardiovascular Research Foundation has announced the late breaking trials and first report investigations that will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2011 scientific symposium. Presented in partnership with the American College of Cardiology (ACC), TCT 2011 is the world's leading educational meeting specializing in interventional cardiovascular medicine and will take place November 7-11, 2011 in San Francisco.

16 Sep 2011

CRF announces late breaking trials & first report investigations to be presented at TCT 2011

The Cardiovascular Research Foundation has announced the late breaking trials and first report investigations that will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2011 scientific symposium. Presented in partnership with the American College of Cardiology (ACC), TCT 2011 is the world’s leading educational meeting specializing in interventional cardiovascular medicine and will take place November 7-11, 2011 in San Francisco.

15 Sep 2011

New clinical data shows positive long-term performance of Medtronic's CoreValve system

New clinical data presented today at the European Society of Cardiology Congress 2011 demonstrate positive long-term performance for the CoreValve transcatheter aortic valve replacement system from Medtronic, Inc.

From Medtronic 29 Aug 2011

Merck secures worldwide rights to vernakalant i.v.

Merck, known as MSD outside the United States and Canada, and Astellas US LLC, the U.S. subsidiary of Astellas Pharma Inc. today announced that they have entered into an agreement under which Merck, through a subsidiary, will acquire the exclusive rights to develop and commercialize the investigational intravenous formulation of vernakalant (vernakalant i.v.) in Canada, Mexico and the United States from Astellas.

27 Jul 2011

Heart experts begin to test new device for treatment of blocked aortic valves

Heart experts at Johns Hopkins have begun testing a new device designed to replace blocked aortic valves in patients for whom traditional open-heart surgery is considered too risky, such as elderly patients and those with other serious medical conditions.

13 Jul 2011

First transcatheter aortic valve implantation performed at Loyola University Hospital

Toni Meyer's heart-valve disease was so severe that she suffered shortness of breath even while sitting in a chair. But after Loyola University Hospital physicians replaced her diseased aortic valve in a catheter procedure as part of a clinical trial, Meyer said she is feeling "100 percent better."

From Medtronic 7 Jul 2011